Disciplined Investments, LLC Arcus Biosciences, Inc. Transaction History

Disciplined Investments, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 10, 2023	BUY	$16.97 - $22.03 $33 - $44	2 Added 100.0%	4 $0
Q1 2023 May 10, 2023	SELL	$15.96 - $23.15 $79 - $115	-5 Reduced 71.43%	2 $0
Q4 2022 Feb 01, 2023	BUY	$19.7 - $35.71 $59 - $107	3 Added 75.0%	7 $0
Q3 2022 Nov 03, 2022	BUY	$23.23 - $30.07 $46 - $60	2 Added 100.0%	4 $0
Q1 2022 Apr 22, 2022	BUY	$28.92 - $41.83 $57 - $83	2 New	2 $0

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Disciplined Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Disciplined Investments, LLC with notifications on news.